THE E ROLE LE AND R RESP SPONSI SIBILITY O OF THE PHARMACEUTI - - PowerPoint PPT Presentation

Merck KGaA

Darm stadt, Germ any

Stefan Oschmann, IFPMA President Chairman of the Executive Board & CEO, Merck KGaA, Darmstadt, Germany Boston, September 15, 2016

THE E ROLE LE AND R RESP SPONSI SIBILITY O OF THE PHARMACEUTI TICAL I INDUSTR TRY I IN THE PREVEN ENTION, , TREATM TMENT T AND C D CURE OF OF PUBLIC H HEALTH P PRIOR ORITY DISEASES ES G GLOBALL LLY

3 Role of Pharm a I ndustry l September 2016

IFPMA A trusted partner in global health

At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people

• everywhere. We collaborate with:

Patient Groups and Coalitions Health Professionals Business NGOS Decision Makers

Role of Pharm a I ndustry l September 2016 4

Global health – a changing landscape Key changes and em erging trends are setting the scene

Key changes Description Health transition: Epidem iologic and dem ographic changes

• Rise of NCDs
• Ageing populations
• Injuries
• Large youth population in developing countries

Outbreaks and global threats

• Concern over new pandemics and epidemics
• Antimicrobial resistance

Environm ental threats

• Effects of climate change on health
• Environmental degradation

Econom ic developm ents

• Transition of LICs to MICs
• Increased importance of domestic financing
• Catastrophic health expenses

Political developm ents

• Rise of large MICs as regional and global powers

Role of Pharm a I ndustry l September 2016 5

Pharmaceutical industry engagement From philanthropy to partnerships

Traditional aid  Mainly government-led health and aid initiatives  Few NGOs (e.g. Médecins Sans Frontières, founded in 1971)

3 2 1

Philanthropy  Mectizan Donation Program (1987)  Bill & Melinda Gates Foundation (1999) Partnerships  Gavi Alliance (2000)  The Global Fund (2002)  Gates CEO Roundtable on NTDs (2012)  Global Financing Facility for reproductive, maternal, newborn, child & adolescent health (2015)  AMR declaration (2016)  Today: over 300 health partnerships implemented by the pharmaceutical industry

6 Role of Pharm a I ndustry l September 2016

• 1.7 billion people affected
• 3 billion people are at risk
• 500,000 people will die annually

Neglected Tropical Diseases (NTDs) London Declaration: an unprecedented collaborative effort

Uniting to Com bat NTDs, Reaching the Unreached, 4t h Progress Report of the London Declaration Uniting to Com bat NTDs, Reaching the Unreached, 4t h Progress Report of the London Declaration

7 Role of Pharm a I ndustry l September 2016

Neglected Tropical Diseases (NTDs) Countries Significant progress has already been achieved

2.4 bi billion t tabl ablets do donated i in 2015 1.5 million

• n treatmen

ents 11.7% i increase from 2014 014

Uniting to Com bat NTDs, Reaching the Unreached, 4t h Progress Report of the London Declaration

Lym phatic filariasis ( LF) LF showed the greatest increase of all diseases treated by MDA in 2014 (40.7% to 50.2% ) and reached the largest number

• f people globally.

Role of Pharm a I ndustry l September 2016 8

Neglected Tropical Diseases (NTDs) I ncreasing treatm ent coverage ( four exam ples)

50.2 % 83 % 84 %

Schistosom iasis There has been a great progress in the past year. Drug donations reached 100 million tablets in 2015, provided by Merck KGaA, Darmstadt, Germany. Guinea w orm disease The global Guinea worm eradication program has made extraordinary

• progress. The number of

human cases was reduced by 83% (22 vs. 126 in 2014). Visceral leishm aniasis The percentage of patients treated with AmBisome in Asia increased to 84% in 2015 – a significant leap from the treatment rate of 10% in 2010.

Uniting to Com bat NTDs, Reaching the Unreached, 4t h Progress Report of the London Declaration

100

million tablets

9 Role of Pharm a I ndustry l September 2016

Nearly 260 million people in Africa suffer from the tropical disease schistosom iasis, resulting in 200,000 deaths a year. In children, the parasitic worm disease stunts growth and reduces their ability to learn. Together with W HO, we have taken up the fight against this

• condition. Thanks to our praziquantel tablets, 7 4 m illion patients

have already received treatment – most of them children. And we intend to continue the fight – until schistosom iasis has been elim inated in Africa.

Neglected Tropical Diseases (NTDs) Our contribution: elim inating schistosom iasis

10 Role of Pharm a I ndustry l September 2016

Antimicrobial Resistance (AMR) A serious public health threat

WHO, AMR fact sheet # 194, April 2015 I FPMA, Rethinking the Way We Fight Bacteria

Call to action signed by:

• 85 companies: pharmaceutical, generics, diagnostics &

biotechnology companies

• 9 industry associations

Signatories com m it to:

• Reducing the development of drug resistance
• Increasing investment in R&D that meets global public

health needs

• Improve access to high-quality antibiotics for all

Joint I ndustry Declaration on Com bating Antim icrobial Resistance ( January 2 0 1 6 )

AMR in 2 0 5 0

10,000,000

AMR in 2 0 1 4

700,000

11 Role of Pharm a I ndustry l September 2016

Non-Communicable Diseases (NCDs) Tackling a grow ing global burden

Medicines in Developm ent ( selected categories, 2 0 1 5 )

I FPMA, The Pharmaceutical I ndustry and Global Health, 2015

W HO NCD Voluntary Global Targets

• 25% reduction in the overall

mortality from CVD, cancer, diabetes,

• r chronic respiratory diseases
• 25% reduction in the prevalence of

raised blood pressure

• Halt the rise of diabetes and obesity
• At least 50% of eligible people

receive drug therapy and counselling to prevent heart attacks and strokes

• 80% availability of basic technologies

and essential medicines required to treat major NCDs

(9 goals overall, all changes against baseline, text shortened for display reasons)

12 Role of Pharm a I ndustry l September 2016

Innovative approaches Addressing access challenges holistically

13 Role of Pharm a I ndustry l September 2016

Industry commitment Sustainable and transform ational health partnerships

I FPMA Developing World Health Partnerships Directory

Build stronger health systems, improve healthcare access, health awareness, and training Pioneer innovative tools and approaches Improve scientific knowledge in low- and middle-income countries and discover new medicines and vaccines Help economies grow by improving health in developing countries

14 Role of Pharm a I ndustry l September 2016

Tackling global health challenges

Chatham House, “Rethinking the Global Health System,” September 2015

The industry is ready to w ork w ith stakeholders from all sectors

States and international

• rganizations

Global health partnerships Non-state actors

 UNITAID  Gavi  Global Fund  Other global health partnerships  Multilateral and regional development banks  WHO  Regional

• rganizations

 National governments  UN agencies  Clubs: G7, G20  Philanthropic

• rganizations

 Professional

• rganizations

 Global civil society and non- governmental

• rganizations

 Private industry  Academic institutions

Role of Pharm a I ndustry l September 2016 15

The industry has proposed eight guiding principles Universal Health Coverage (UHC)

I FPMA, I nnovative Biopharm aceutical I ndustry Perspectives on UHC, Proposed public Policy Perspectives I FPMA, Translating Principles into Practice

I ndustry w orking collaboratively to support countries to achieve the UHC target 1 . Equitable Access: Roche Scientific Partnership for HER2 Testing Excellence 2 . Efficiency: 4 Healthy Habits 3 . Quality: Global Pharma Health Fund (GPHF) 4 . I nclusiveness: Boehringer Ingelheim – Making More Health 5 . Availability: Pfizer International Trachoma Initiative (ITI) 6 . Adaptability: Sanofi Next Billion Patients in Egypt 7 . Choice: Astra Zeneca Young Health Program 8 . I nnovation: Global Health Innovation Technology Fund (GHIT)

16 Role of Pharm a I ndustry l September 2016

Outlook Concerted action is the key to achieving Universal Health Coverage ( UHC)

Everyone has a seat at the table Establish common ground and agree on roles & responsibilities Communicate continuously to establish trust and governance principles emphasizing transparency and accountability Build on existing learnings Stepwise approach to tackling challenges Work together on improving the predictability of markets and their enabling environment for optimum outcomes Invest in robust monitoring and evaluation capabilities to inform sustainability planning